Detalhe da pesquisa
1.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Br J Haematol
; 195(2): 201-209, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34341990
2.
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Int J Cancer
; 139(1): 177-86, 2016 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26891420
3.
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Lancet Oncol
; 14(1): 55-63, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23182627
4.
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Front Immunol
; 14: 1239082, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37954584
5.
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
J Clin Med
; 12(2)2023 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36675328
6.
VISTA expression and patient selection for immune-based anticancer therapy.
Front Immunol
; 14: 1086102, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36891296
7.
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol
; 33(24): 2667-74, 2015 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26169611
8.
Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008.
Clin Cancer Res
; 19(21): 5984-93, 2013 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24045184
9.
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Cancer Med
; 2(6): 925-32, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24403266
10.
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Clin Lung Cancer
; 13(5): 391-5, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22440336
11.
Monoclonal antibody dose determination and biodistribution into solid tumors.
Ther Deliv
; 2(3): 333-44, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22834004
12.
A recent illustration of some essentials of circadian chronotherapy study design.
J Clin Oncol
; 22(14): 2971-2; author reply 2972, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15254067